Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.
about
Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer
P2860
Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Phase II trial of dose dense d ...... s with operable breast cancer.
@en
Phase II trial of dose dense d ...... s with operable breast cancer.
@nl
type
label
Phase II trial of dose dense d ...... s with operable breast cancer.
@en
Phase II trial of dose dense d ...... s with operable breast cancer.
@nl
prefLabel
Phase II trial of dose dense d ...... s with operable breast cancer.
@en
Phase II trial of dose dense d ...... s with operable breast cancer.
@nl
P2093
P1476
Phase II trial of dose dense d ...... s with operable breast cancer.
@en
P2093
Andrew Kramar
Frédéric Bibeau
Gilles Romieu
Jean-Pierre Bleuse
Marian Gutowski
Pierre-Emmanuel Colombo
Sophie Gourgou-Bourgade
William Jacot
P304
P356
10.1097/COC.0B013E3181BEAD47
P577
2010-12-01T00:00:00Z